Related references
Note: Only part of the references are listed.Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
Katerina Shulman et al.
CANCER (2011)
Significance of differential expression of thymidylate synthase in normal and primary tumor tissues from patients with colorectal cancer
Yanyan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
David Z. Chang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy
Z. Kleibl et al.
NEOPLASMA (2009)
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
E. Rouits et al.
BRITISH JOURNAL OF CANCER (2008)
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
Chun-Yu Liu et al.
CANCER (2008)
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations
A. Zhang et al.
PHARMACOGENOMICS JOURNAL (2007)
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American
N Kaniwa et al.
DRUG METABOLISM AND DISPOSITION (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene
MH Wu et al.
PHARMACOGENETICS (2004)
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
L Paoluzzi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
V Charasson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen
M Ychou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma
NE Schoemaker et al.
THERAPEUTIC DRUG MONITORING (2003)
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency:: High prevalence of the IVS14+1G>A mutation
ABP Van Kuilenburg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Share Paper
